AR and prostate cancer: Although ARD-266 incorporates a VHL ligand with relatively weak binding affinity (Ki in the low micromolar range), it achieves potent Aryl degradation with DC50 values ranging from 0.2 to 1 nM in AR-positive prostate cancer cells.